Skip to main content

Advertisement

Table 1 Patients demographics and clinico-pathological characteristics for phase I and II enrolled pancreatic cancer patients (N = 75)

From: Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

  Enrolled patients (N = 75) (%)
Age group
 Median (range) 62.8 (44–83)
 < 60 27 (36%)
 ≥ 60 48 (64%)
Sex
 Male to female ratio 1.7:1
 Female 28 (37.3%)
 Male 47 (62.7%)
Race
 White 61 (81.3%)
 Black 4 (5.3%)
 Hispanic 4 (5.3%)
 Asian 4 (5.3%)
 Others 2 (2.7%)
Tumor differentiation
 Moderate 22 (29.3%)
 Poor 23 (30.7%)
 Unknown 30 (40%)
ECOG
 0 8 (10.7%)
 1 67 (89.3%)
Tumor location
 Head 22 (29.3%)
 Body 32 (42.7%)
 Tail 19 (25.3%)
 Unknown 2 (2.7%)
Site of metastasis
 Liver 61 (75.3%)
 Lung 10 (12.3%)
 Peritoneal 15 (18.5%)
 Others 4 (5.3%)
CA19-9 (U/ml)
 Median (range) 58,159.1 (0.9–58,160)
 ≤ 35 12 (16%)
 > 35 63 (84%)
Previous treatment
 De novo 69 (92%)
 Surgery 4 (4.9%)
 Chemotherapy 4 (4.9%)